}

Siponimod

Immunosuppressants (Sphingosine-1-Phosphate Receptor Modulator)

Drug Overview

Siponimod, marketed under the brand name Mayzent, is an oral sphingosine-1-phosphate (S1P) receptor modulator used in the management of multiple sclerosis.

It is indicated for relapsing forms of multiple sclerosis, including secondary progressive MS with active disease. Siponimod binds selectively to S1P₁ and S1P₅ receptors on lymphocytes, preventing their egress from lymph nodes and reducing inflammatory damage in the central nervous system.

Relevant Genes and Their Roles

The primary gene affecting siponimod metabolism is CYP2C9, which encodes a cytochrome P450 enzyme in the liver responsible for converting siponimod into inactive metabolites. Cytochrome P450 enzymes process many medications, influencing drug clearance.

Genetic variants in CYP2C9 can decrease or increase enzyme activity. Reduced‐function alleles slow metabolism, raising drug exposure and risk of adverse effects, while increased‐function alleles may clear the drug too quickly, risking subtherapeutic levels.

Impact of Genetics on Drug Response

CYP2C9 genotypes classify patients into ultra‐rapid/rapid, normal, intermediate, and poor metabolizers, which directly influence siponimod plasma concentrations. Poor metabolizers have significantly higher exposure and greater risk of toxicity, intermediate metabolizers require dose adjustment, and ultra‐rapid metabolizers may clear the drug more quickly, potentially reducing efficacy.

Expected Clinical Effects of Genetic Variation

Ultra-rapid/Rapid Metabolizer

  • Effect: Decreased siponimod levels due to rapid clearance
  • Clinical consequence: Potential reduced efficacy in controlling disease activity
  • Side effects: Generally few; under-treatment may occur, low severity, infrequent

Normal Metabolizer

  • Effect: Expected siponimod levels within the therapeutic range
  • Clinical consequence: Standard efficacy and safety profile
  • Side effects: Typical tolerability; mild to moderate, as observed in clinical trials

Intermediate Metabolizer

  • Effect: Moderately increased siponimod exposure
  • Clinical consequence: Enhanced efficacy but higher risk of dose‐related adverse effects
  • Side effects: Mild to moderate; may include bradycardia or elevated liver enzymes, occasional frequency

Poor Metabolizer

  • Effect: Significantly increased siponimod levels
  • Clinical consequence: High risk of toxicity and adverse events
  • Side effects: Severe; bradycardia, hypertension, liver toxicity may occur more frequently

Indeterminate/Not Available

  • Effect: Unknown impact on siponimod levels
  • Clinical consequence: No specific guidance; follow standard dosing with close monitoring
  • Side effects: Unknown; monitor for typical siponimod‐related events

Dosing Guidelines

The following dosing guidelines are based on the available guidelines for CYP2C9 genotypes from the FDA.

CYP2C9 Dosing Guideline

Phenotype Clinical Consequence Guideline Recommendation
Normal Metabolizer Expected siponimod exposure and efficacy similar to clinical trial population Initiate with standard titration: 0.25 mg once daily for 4 days, 0.5 mg once daily for 3 days, 0.75 mg once daily for 3 days, then maintenance dose of 2 mg once daily.
Intermediate Metabolizer Increased siponimod exposure and higher systemic concentration Use reduced maintenance dose: follow standard titration, then maintain at 1 mg once daily.
Poor Metabolizer Significantly increased siponimod exposure; elevated risk of adverse effects Contraindicated; do not use siponimod in patients with CYP2C9 *3/*3 genotype.
Indeterminate Unknown impact Initiate therapy with recommended starting dose (standard titration).
Not available Unknown impact Initiate therapy with recommended starting dose (standard titration).

Alternative Treatment Options

For patients with reduced or absent CYP2C9 activity who cannot take siponimod, alternative multiple sclerosis therapies such as fingolimod, ozanimod, or other disease-modifying treatments may be considered. These examples are based on guideline recommendations and are not medical advice.

Sources and References

Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested